netFormulary Dorset NHS
The Dorset Formulary has been developed in associations with
NHS Dorset Clinical Commissioning Group
Dorset County Hospital NHS Foundation Trust
Dorset Healthcare University NHS Foundation Trust
Poole Hospital NHS Foundation Trust
Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust
 
 Search
 Formulary Chapter 5: Infections - Full Chapter
Notes:

Chapter review date:

Chapter Links...
 Details...
05.03.04  Expand sub section  Influenza
Amantadine Hydrochloride (Lysovir®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
Use in accordance with NICE TA158. 
Link  NICE TA158 Amantadine, oseltamivir and zanamivir for the treatment of influenza
   
Oseltamivir (Tamiflu®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
For influenza prophylaxis in accordance with NICE TA158 and NICE TA168.

For the treatment of influenza in adults and children if all the following circumstances apply:

•national surveillance schemes indicate that influenza virus A or B is circulating
•the person is in an 'at-risk' group as defined in the guidance
•the person presents with an influenza-like illness and can start treatment within 48 hours (or within 36 hours for zanamivir treatment in children) of the onset of symptoms as per licensed indications.

Vaccination, particularly targeting "high risk" patients, remains the mainstay of influenza management.
 
Link  May 2018: Flu Season has ended- CAS Alert
Link  NICE TA158. oseltamavir, amantadine (review) and zanamavir for the prophylaxis of influenza
Link  NICE TA168 Amantadine, oseltamivir and zanamivir for the treatment of influenza
   
Zanamivir dry powder for inhalation (Relenza®)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Green
For influenza prophylaxis and treatment in accordance with NICE recommendations (TAs 158 and 168).

For the treatment of influenza in adults and children if all the following circumstances apply:

•national surveillance schemes indicate that influenza virus A or B is circulating
•the person is in an 'at-risk' group as defined in the guidance
•the person presents with an influenza-like illness and can start treatment within 48 hours (or within 36 hours for zanamivir treatment in children) of the onset of symptoms as per licensed indications.


Vaccination particularly targeting 'high risk' patients remains the mainstay of influenza management.
 
Link  May 2018: Flu Season has ended- CAS Alert
Link  NICE TA 158: oseltamavir, amantadine (review) and zanamavir for the prophylaxis of influenza
Link  NICE TA 168: amantadine, oseltamavir and zanamavir for the treatment of influenza
   
 ....
 Non Formulary Items
Zanamivir Injection

Track Changes
Non Formulary May be obtained from GSK on compassionate grounds for named patients for nebulistation or IV administration - for criteria see latest DH guidelines
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

May be initiated, stabilised and maintained in primary, secondary or tertiary care  

Amber

Amber drug - without shared care  

Amber SCG

Amber drug - with shared care guideline  

Red

For secondary or tertiary care initiation and long-term maintenance of prescribing  

Black

Not recommended  

netFormulary